A survey of women with breast cancer found that nearly half considered having a double mastectomy. But of those who considered it, only 37 percent knew that the more aggressive procedure does not improve survival for women with breast cancer.
Why do some cancer cells break away from a tumor and travel to distant parts of the body? A team of oncologists and engineers from the University of Michigan teamed up to help understand this crucial question.
In a major advance in precision medicine, an international collaboration of researchers found 90 percent of castration resistant metastatic prostate cancers harbored some kind of genetic anomaly that could drive treatment choices.
A new urine-based test improved prostate cancer detection – including detecting more aggressive forms of prostate cancer – compared to traditional models based on prostate serum antigen, or PSA, levels, a new study finds.
The American Cancer Society's estimates for brain and spinal cord tumors in the United States are for 2015. They include both adults and children.
About 22,850 malignant tumors of the brain or spinal cord (12,900 in males and 9,950 in females) will be diagnosed. These numbers would likely be much higher if benign tumors were also included.
Researchers have developed and tested a new tool that searches for the most common genetic anomalies seen in cancer. The assay demonstrates the ability to make gene sequencing easier over a large volume of samples. In the future, this may mean that patients would not always need to undergo a fresh biopsy in order to identify a potential treatment strategy, as is currently necessary with more comprehensive sequencing approaches.
At the University of Michigan Rogel Cancer Center, our Multiple Myeloma Program has a number of studies underway that are only available to our patients. We have extensive experience in selecting the right trial for each person.
Below is a list of some of the open trials. If you see one you may be eligible for or have questions, please call 800-865-1125 (Monday-Friday, 8am-5pm EST).
The sarcoma survivorship clinic is not seeing patients at this time. Please call our Cancer AnswerLine™ at 800-865-1125 for information on who can help you with your survivorship questions.
MENU